Table 1 Patient and treatment characteristics
Patient characteristics | N = 10 |
n (%) | |
Median age (range) years | 66 (55–77) |
Female gender | 5 (50%) |
ECOG performance status ≥ 2 | 2 (20%) |
Ethnicity | |
Hispanics | 4 (40%) |
White | 3 (30%) |
African American | 2 (20%) |
Asian | 1 (10%) |
Disease characteristics | n (%) |
Non-GCB DLBCL | 4 (40%) |
Transformed lymphoma | 3 (30%) |
Double expressor lymphoma | 6 (60%) |
Triple expressor lymphoma | 2 (20%) |
Double hit lymphoma | 1 (10%) |
Triple hit lymphoma | 1 (10%) |
P53 deletion by FISH | 1 (10%) |
Disease stage | |
Stage I | 0 |
Stage II | 1 (10%) |
Stage III | 4 (40%) |
Stage IV | 5 (50%) |
Number of prior lines of therapy | |
1 | 0 |
2 | 2 (20%) |
3 | 3 (30%) |
4 | 5 (50%) |
CNS involvement | 2 (20%) |
Prior AHCT | 7 (70%) |
Response to treatment | n (%) |
CR at 3 months | 8 (80%) |
POD | 1 (10%) |
Adverse events | |
CRS | 6 (60%) |
CRS grade ≥ 2 | 2 (20%) |
ICANS | 5 (50%) |
ICANS grade ≥ 2 | 3 (30%) |
Tocilizumab | 3 (30%) |
Glucocorticoids | 1 (10%) |
Neutropenia (< 500 c/μl) | 10 (100%) |
Neutropenic fever | 8 (80%) |
Thrombocytopenia (< 50,000 c/μl) | 7 (70%) |
Documented infection | 5 (50%) |